4/17
02:32 pm
cstl
The Melanoma Research Foundation Launches its Inaugural Washington DC 5K Fundraiser with a Goal of $115,000 in Support of Melanoma Research, Education and Advocacy
Low
Report
The Melanoma Research Foundation Launches its Inaugural Washington DC 5K Fundraiser with a Goal of $115,000 in Support of Melanoma Research, Education and Advocacy
4/15
10:43 am
cstl
Castle Biosciences inks expansion at Nova Place [Yahoo! Finance]
Neutral
Report
Castle Biosciences inks expansion at Nova Place [Yahoo! Finance]
4/15
07:09 am
cstl
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 [TheStreet.com]
Low
Report
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 [TheStreet.com]
4/15
07:00 am
cstl
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Low
Report
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
4/10
07:00 am
cstl
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Low
Report
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
4/4
07:25 pm
cstl
How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) [Yahoo! Finance]
Low
Report
How Revenue Assumptions Are Rewriting The Story For Castle Biosciences (CSTL) [Yahoo! Finance]
3/27
09:40 am
cstl
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 [TheStreet.com]
Low
Report
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 [TheStreet.com]
3/27
09:05 am
cstl
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Medium
Report
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
3/23
09:17 pm
cstl
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript [Seeking Alpha]
Low
Report
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript [Seeking Alpha]
3/23
06:54 pm
cstl
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk [Yahoo! Finance]
Low
Report
Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk [Yahoo! Finance]
3/21
12:35 am
cstl
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets [Yahoo! Finance]
Medium
Report
Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets [Yahoo! Finance]
3/13
11:45 am
cstl
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB [Yahoo! Finance]
Low
Report
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB [Yahoo! Finance]
3/13
11:02 am
cstl
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Low
Report
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
3/13
03:53 am
cstl
SciBase: Interim report [Yahoo! Finance]
Low
Report
SciBase: Interim report [Yahoo! Finance]
3/9
07:32 am
cstl
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk [Yahoo! Finance]
Low
Report
DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk [Yahoo! Finance]
3/9
07:00 am
cstl
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Low
Report
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
3/4
04:58 pm
cstl
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB [Yahoo! Finance]
Low
Report
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB [Yahoo! Finance]
3/4
04:30 pm
cstl
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Low
Report
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
3/4
05:51 am
cstl
Castle Biosciences (CSTL) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Castle Biosciences (CSTL) was downgraded by Zacks Research from "strong-buy" to "hold".
3/3
05:00 pm
cstl
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas [Yahoo! Finance]
Low
Report
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas [Yahoo! Finance]
3/3
04:30 pm
cstl
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Low
Report
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
3/2
07:01 am
cstl
Castle Biosciences (CSTL) was upgraded by Morgan Stanley to "buy".
Medium
Report
Castle Biosciences (CSTL) was upgraded by Morgan Stanley to "buy".
2/27
08:02 am
cstl
Castle Biosciences (CSTL) had its price target raised by Robert W. Baird from $41.00 to $44.00. They now have an "outperform" rating on the stock.
Medium
Report
Castle Biosciences (CSTL) had its price target raised by Robert W. Baird from $41.00 to $44.00. They now have an "outperform" rating on the stock.
2/26
05:59 pm
cstl
Castle Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Castle Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
04:32 pm
cstl
Castle Biosciences Non-GAAP EPS of -$0.08 beats by $0.18, revenue of $87M beats by $6.69M [Seeking Alpha]
High
Report
Castle Biosciences Non-GAAP EPS of -$0.08 beats by $0.18, revenue of $87M beats by $6.69M [Seeking Alpha]